Welcome to our dedicated page for Senseonics SEC filings (Ticker: SENS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Senseonics Holdings, Inc. filings document the public-company disclosures of a medical technology issuer commercializing implantable continuous glucose monitoring products for diabetes care. Its Form 8-K reports furnish operating results and business updates for Eversense CGM systems, including commercialization activity, clinical or regulatory disclosures, product integrations and financial outlook commentary.
The company’s regulatory record also covers capital-structure and financing matters, including public offerings of common stock and pre-funded warrants and amendments to debt arrangements. Proxy materials disclose board elections, executive compensation votes, auditor ratification, authorized-share proposals and equity incentive plan matters. A Form 25 filing documents the voluntary withdrawal of Senseonics common stock from listing and registration on NYSE American.
Senseonics Holdings, Inc. entered an underwriting agreement to sell 8,000,000 shares of common stock and 8,000,000 pre-funded warrants at $5.00 per share or $4.999 per warrant, for expected net proceeds of about $74.7 million, or $86.0 million if underwriters fully exercise a 2,400,000-share option.
For the quarter ended March 31, 2026, the company preliminarily expects revenue of approximately $11.7 million, gross profit of about $6.4 million with a gross margin near 54%, and a net loss between $31 million and $33 million, with cash and equivalents around $64.6 million and stockholders’ equity between $33.7 million and $35.7 million.
Through a non-binding term sheet with Hercules Capital, Senseonics proposes to expand its Loan and Security Agreement capacity from $100.0 million to $140.0 million, including $20.0 million of near-term commitments and up to $85.0 million in additional future tranches, which would have resulted in about $55.0 million of total debt outstanding as of December 31, 2025 on an as-adjusted basis.
Senseonics Holdings, Inc. is offering securities in a primary offering under a preliminary prospectus supplement dated April 30, 2026, registering an $80 million offering of common stock and pre-funded warrants to purchase shares of common stock. The offering is made pursuant to an existing Form S-3 shelf registration (File No. 333-289306) declared effective August 18, 2025. The prospectus supplement states the company expects net proceeds to fund the ongoing launch of Eversense 365, pipeline development, working capital and general corporate purposes. The cover discloses a last reported Nasdaq sale price of $6.43 per share on April 29, 2026. The prospectus supplement also discloses preliminary first-quarter 2026 financial estimates, including revenue of approximately $11.7 million, gross profit of approximately $6.4 million, net loss between $31 million and $33 million, and cash and equivalents of approximately $64.6 million. The offering includes pre-funded warrants exercisable for $0.001 per share, a 9.99% beneficial ownership exercise limitation (adjustable to 19.99% with notice), and an underwriter option for additional shares for 30 days.
Senseonics Holdings, Inc. is offering securities in a primary offering under a preliminary prospectus supplement dated April 30, 2026, registering an $80 million offering of common stock and pre-funded warrants to purchase shares of common stock. The offering is made pursuant to an existing Form S-3 shelf registration (File No. 333-289306) declared effective August 18, 2025. The prospectus supplement states the company expects net proceeds to fund the ongoing launch of Eversense 365, pipeline development, working capital and general corporate purposes. The cover discloses a last reported Nasdaq sale price of $6.43 per share on April 29, 2026. The prospectus supplement also discloses preliminary first-quarter 2026 financial estimates, including revenue of approximately $11.7 million, gross profit of approximately $6.4 million, net loss between $31 million and $33 million, and cash and equivalents of approximately $64.6 million. The offering includes pre-funded warrants exercisable for $0.001 per share, a 9.99% beneficial ownership exercise limitation (adjustable to 19.99% with notice), and an underwriter option for additional shares for 30 days.
Senseonics Holdings, Inc. is soliciting proxies for its virtual 2026 Annual Meeting on May 20, 2026 to elect three Class I directors, seek advisory votes on executive compensation and frequency, ratify KPMG as auditor, approve doubling authorized common stock to 140,000,000 shares, and approve a new 2026 Equity Incentive Plan.
The record date is March 26, 2026, with 41,795,466 shares outstanding on that date. The proxy explains voting mechanics, vote thresholds, broker voting treatment (Proposals 1,2,3,6 are non-routine), and discloses reserved shares and recent financial context including $15.8M gross profit for the twelve months ended December 31, 2025 and an accumulated deficit of $1 billion.
Senseonics Holdings, Inc. is holding a virtual 2026 Annual Meeting on May 20, 2026 to vote on six key proposals. Stockholders will elect three directors, cast advisory votes on executive pay and its frequency, and ratify KPMG LLP as auditor for 2026.
The company is asking investors to approve an amendment to double authorized common stock from 70,000,000 to 140,000,000 shares and to approve a new 2026 Equity Incentive Plan. Common shares outstanding were 41,795,466 as of March 26, 2026, with 14,233,357 additional shares reserved for incentives and warrants.
ROEDER DOUGLAS A reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings director Douglas A. Roeder received 2,218 shares of common stock as a grant in lieu of cash board fees. The shares were valued at $6.65 each, matching the Nasdaq closing price on April 1, 2026, for a total of $14,749.70 in compensation value.
This was a compensation-related award under the company’s non-employee director compensation policy, not an open-market purchase. After this grant, Roeder directly holds 121,949 shares of Senseonics common stock.
Prince Douglas S reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings, Inc. director Douglas S. Prince received 1,221 shares of common stock on April 1, 2026 as a grant. The shares were issued under the non-employee director compensation policy in lieu of quarterly retainer fees, based on $8,119.65 divided by the $6.65 closing price. Following this award, he directly holds 57,964 common shares.
Fiorentino Edward reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings, Inc. reported that director Edward Fiorentino received a grant of common stock as board compensation. On April 1, 2026, he was issued 2,124 shares under the non-employee director compensation policy in lieu of a $14,124.60 quarterly cash retainer at $6.65 per share. Following this award, he directly holds 73,487 shares of Senseonics common stock.
Steven Edelman reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings director Steven Edelman received a stock grant as part of his board compensation. He was awarded 1,936 shares of common stock, valued at $12,874.40 based on a $6.65 closing price on April 1, 2026, in lieu of quarterly cash retainer fees.
Following this grant, Edelman directly holds 78,829 shares of Senseonics common stock. This was a compensation-related award rather than an open-market purchase or sale, and no derivative securities are reported in this filing.
Senseonics Holdings, Inc. is soliciting proxies for its virtual 2026 Annual Meeting to be held on May 20, 2026. The record date is March 26, 2026, when 41,795,466 shares were outstanding. Key proposals include the election of three Class I directors (Timothy T. Goodnow, Francine R. Kaufman and Sharon Larkin), an advisory say-on-pay vote and a say-on-frequency vote, ratification of KPMG LLP as independent auditors, approval to increase authorized common shares from 70,000,000 to 140,000,000, and approval of the Senseonics Holdings, Inc. 2026 Equity Incentive Plan.
The proxy discloses reserve and capitalization context as of the record date: 41,795,466 shares outstanding, aggregate reserved shares of 14,233,357 across plans and warrants, and 13,971,177 unissued, unreserved shares. The company reported $15.8 million gross profit for the twelve months ended December 31, 2025 and an accumulated deficit of $1 billion. The Board recommends a vote FOR all proposals.